Market Reports

Meeting the global demand for high quality pharmaceutical packaging

Meeting the global demand for high quality pharmaceutical packaging

Amidst a flurry of recent announcements at the recent DCAT Week in New York, Dr Kevin Robinson sat down with Dr Frank Heinricht, Chairman of the Management Board of SCHOTT AG, to discover how the company is addressing issues in the pharmaceutical value chain, from glass tubing to packaging and the application of artificial intelligence
Continuous manufacturing: making it real

Continuous manufacturing: making it real

Industry pioneers GEA, Siemens and Perceptive Engineering recently hosted the inaugural Reality of Continuous Pharmaceutical Manufacturing conference in Durham, UK, to examine the current status of going conti and present real-life applications to an international audience. Dr Kevin Robinson reports
Global serialisation: Russian track and trace readiness

Global serialisation: Russian track and trace readiness

Christoph Krähenbühl, Senior Director of Excellis Europe, explains the challenge that the new Russian traceability regulations present to the pharma industry and how all participants in the supply chain must properly prepare to ensure that they become compliant within this new environment
Backend, baffling and buzzing: blockchain

Backend, baffling and buzzing: blockchain

Marco Mohwinckel, healthcare executive and adviser, takes a closer look at the invisible backend technology that has been touted as a revolution
Digitalisation in specialty chemicals and pharmaceuticals

Digitalisation in specialty chemicals and pharmaceuticals

Paige Marie Morse, Industry Director, AspenTech talks to Dr Kevin Robinson about accelerating innovation and optimising the value chain with digital technologies
Supporting precision with precision

Supporting precision with precision

As biologics steadily grow in pipeline development and commercialisation, they inherently require precise and meticulous support to ensure effective delivery to the patient
The economic advantages of continuous flow chemistry

The economic advantages of continuous flow chemistry

Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit
The modularisation of chemical API synthesis

The modularisation of chemical API synthesis

The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers
Rare diseases: understanding the patient journey

Rare diseases: understanding the patient journey

In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research
A new paradigm in vaccines and cancer treatments

A new paradigm in vaccines and cancer treatments

Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Dr Kevin Robinson recently caught up with Nigel Theobald, CEO of N4 Pharma, to find out more
Fuelling pharma’s innovation engines

Fuelling pharma’s innovation engines

Wishing to assess the current state of Alcami’s target market, Dr Kevin Robinson recently sat down with President and CEO, Dr Stephan Kutzer, to discuss its health, innovation and future aspirations
Broad stripes, bright stars and a thriving pharmaceutical industry: part I

Broad stripes, bright stars and a thriving pharmaceutical industry: part I

According to one of Stephen Sondheim’s most well-known lyrics, “I like to be in America! OK by me in America!” But, given the geography, politics, population, regulation and funding that are unique to the United States, Dr Kevin Robinson looked west to the Land of the Free to find out how the pharmaceutical industry is faring amongst all the milk and honey
The hidden risk of contamination

The hidden risk of contamination

Pharmaceutical companies may be unwittingly putting production processes at risk of contamination by fitting pumps with mechanical seals that fail to comply with industry regulations, says John Smiddy, European Sales and Technical Support Director for AESSEAL
A revolutionary method of liquid flow measurement

A revolutionary method of liquid flow measurement

Pharmaceutical supplier opts for innovative hygienic flowmeter
Next-generation safety testing

Next-generation safety testing

In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable
Developments and the future of pharmaceutical packaging

Developments and the future of pharmaceutical packaging

With the global primary packaging market in the pharmaceutical sector expected to experience remarkable growth during the next few years, Dr Kevin Robinson asked a number of industry experts to comment on the hurdles, drivers and emerging trends that are influencing how drugs are formulated, packaged and delivered

Trending Articles

  1. A rules-based approach to labelling and artwork management: Part I Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative, says Graham Francis, Channel Marketing Manager, Kallik
  2. A microfluidic approach to production of alginate beads for cell encapsulation Gurinder Vinner, Material Scientist at Dolomite Microfluidics, discusses the benefits of continuous microfluidic production for the encapsulation of mammalian cells with no loss of viability
  3. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  4. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  5. CMC strategies for the acceleration of commercial-ready ADC manufacturing The potential for antibody-drug conjugate (ADC) programmes to accelerate from early to late stage clinical development highlights the need to establish commercial launch-ready manufacturing early and efficiently, reports Courtney Morgret, Senior Scientist, Manufacturing Sciences, AbbVie

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all